Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Symptomatic gout~* Serum uric acid \>7 mg/dL~* Intolerance of, or inadequate response to, conventional therapy for gout~* Women of childbearing potential must have a negative serum pregnancy test and must use an approved birth control method~Exclusion Criteria:~* End stage renal failure that requires dialysis~* Concurrent use of uric-acid lowering agents~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* A history of anaphylactic reaction to a recombinant protein~* Concurrent use of immunosuppressive therapy (except as needed for prevention of rejection of a transplanted organ, or prednisone at 10 mg a day or less for treatment of gout flares)~* A medical or psychological condition which, in the opinion of the investigator, might create undue risk to the subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pegloticase (Type: EXPERIMENTAL): All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.~There was no control group for this open label study.

Based on this trial design, predict the completion outcome and termination type (if applicable).